Zacks Analyst Blog Highlights Novartis, Duke Energy, Boston Scientific, Norfolk Southern and Cadence Design Systems


For immediate release

Chicago, IL – August 1, 2022 – announces the list of stocks featured in the analyst blog. Every day, Zacks Equity Research analysts discuss the latest news and events impacting stocks and financial markets. Stocks recently featured in the blog include: Novartis AG NVS, Duke Energy Corp. DUK, Boston Scientific Corp. BSX, Norfolk Southern Corp. NSC and Cadence Design Systems, Inc. CDNS.

Here are highlights from Friday’s analyst blog:

Key analyst reports for Novartis, Duke Energy and Boston Scientific

Zacks Research Daily features top research results from our team of analysts. Today’s Research Daily features new research reports on 16 major stocks, including Novartis AG, Duke Energy Corp. and Boston Scientific Corp. These research reports have been handpicked from the approximately 70 reports published by our team of analysts today.

You can see all research reports from today here >>>

Novartis shares have outperformed industry Zacks Large Cap Pharmaceuticals over the past year (+21.0% vs -3.0%). The company’s performance in the second quarter was strong thanks to improved lagging activity from Sandoz and momentum from the cardiovascular drug Entresto. Sandoz’s performance was driven by growth in Europe, both in launches and in the recovery of healthcare systems.

Accordingly, the company also raised the full-year guidance for Sandoz. Drugs like Cosentyx, Entresto, Kesimpta, Zolgensma, Kisqali and Leqvio should continue to fuel growth and offset the impact of generic competition. The launch of additional drugs like Pluvicto, Piqray, Leqvio and Mayzent, and expanding the label of key drugs are also expected to further boost performance.

The progress of the pipeline is impressive and the company has promising candidates. However, generic competition for key drugs and pipeline setbacks pose challenges.

(You can read the full Novartis research report here >>>)

duke energy since the beginning of the year (+5.8% against +2.3%). The company is a leading utility provider investing heavily in infrastructure and expansion projects. During the period 2022-2026, it plans to spend the capital of $63 billion, while $130 billion over the next decade.

It has reduced its carbon emissions by 44% since 2005 and is now expanding its 2050 net zero goals to include scope 2 emissions and some scope 3 emissions. increases by almost 1.5% in 2022. Yet its ability to reach net zero by 2050 at a profitable price could be threatened due to rising prices for technological resources.

In addition, fluctuating energy prices may affect its results. A comparative analysis of its 12-month enterprise value-to-sales ratio shows a bleak picture that may worry investors.

(You can read the full research report on Duke Energy here >>>)

Scientific Boston shares are down -9.7% over the past year against the industry decline of -29.0% Zacks Medical – Products. The company’s rising costs and expenses are putting pressure on its margins. Current macro-environmental challenges related to rising freight costs and rising direct labor wages continue to hamper operations. An unfavorable exchange rate slows growth. The upper end of the adjusted EPS forecast for the full year has been reduced, which increases concerns.

However, Boston Scientific ended the second quarter of 2022 on a bullish note with adjusted earnings and revenue exceeding the Zacks consensus estimate. The company reported a year-over-year improvement in organic sales, indicating a strong rebound in business inherited from the chaos of the pandemic. Organic revenue from each of its main businesses and geographies increased. The rise in organic revenue forecasts for 2022 looks promising.

(You can read the full research report on Boston Scientific here >>>)

Other noteworthy reports we’re featuring today include Norfolk Southern Corp. and Cadence Design Systems, Inc..

Why haven’t you watched Zacks best action?

Our top 5 performing strategies swept away the S&P’s impressive +28.8% gain in 2021. Surprisingly, they soared +40.3%, +48.2%, +67.6%, +94.4%, and +95.3%. Today, you can access their live selections at no cost or obligation.

See Free Stocks >>

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

[email protected]

Past performance is not indicative of future results. The potential for loss is inherent in any investment. This document is provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold any security. No recommendation or advice is given as to whether any investment is suitable for any particular investor. It should not be assumed that investments in the securities, companies, sectors or markets identified and described have been or will be profitable. All information is current as of the date hereof and is subject to change without notice. The views or opinions expressed may not reflect those of the company as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management of securities. These returns come from hypothetical portfolios composed of stocks with Zacks Rank = 1 that have been rebalanced monthly without transaction fees. These are not the returns of actual stock portfolios. The S&P 500 is an unmanaged index. Visit for more information on the performance figures displayed in this press release.

Just Released: Zacks Top 10 Stocks for 2022

In addition to the investment ideas discussed above, would you like to know our top 10 picks for all of 2022?

From its creation in 2012 to 2021, the Zacks Top 10 Stocks portfolios gained an impressive +1,001.2% vs. +348.7% for the S&P 500. Now our research director has combed through 4,000 companies covered by the Zacks Ranking and selected the top 10 tickers to buy and keep. Don’t miss your chance to enter…because the sooner you do, the more chances you have of winning.

See actions now >>

Click to get this free report

Novartis AG (NVS): Free Inventory Analysis Report

Boston Scientific Corporation (BSX): Free Stock Analysis Report

Duke Energy Corporation (DUK): Free Stock Analysis Report

Norfolk Southern Corporation (NSC): Free Stock Analysis Report

Cadence Design Systems, Inc. (CDNS): Free Inventory Analysis Report

To read this article on, click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


Comments are closed.